Literature DB >> 21067510

The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy.

P Anil Kumar1, Frank C Brosius, Ram K Menon.   

Abstract

Involvement of the growth hormone (GH) / insulin-like growth factor 1 (IGF-I) axis in the pathogenesis of diabetic nephropathy (DN) is strongly suggested by studies investigating the impact of GH excess and deficiency on renal structure and function. GH excess in both the human (acromegaly) and in transgenic animal models is characterized by significant structural and functional changes in the kidney. In the human a direct relationship has been noted between the activity of the GH/IGF-1 axis and renal hypertrophy, microalbuminuria, and glomerulosclerosis. Conversely, states of GH deficiency or deficiency or inhibition of GH receptor (GHR) activity confer a protective effect against DN. The glomerular podocyte plays a central and critical role in the structural and functional integrity of the glomerular filtration barrier and maintenance of normal renal function. Recent studies have revealed that the glomerular podocyte is a target of GH action and that GH's actions on the podocyte could be detrimental to the structure and function of the podocyte. These results provide a novel mechanism for GH's role in the pathogenesis of DN and offer the possibility of targeting the GH/IGF-1 axis for the prevention and treatment of DN.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21067510      PMCID: PMC4007067          DOI: 10.2174/157339911794273900

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  79 in total

1.  Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study.

Authors:  Rakesh Amin; Carl Schultz; Ken Ong; Jan Frystyk; R Neil Dalton; Les Perry; Hans Ørskov; David B Dunger
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

Review 2.  Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention.

Authors:  Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

Review 3.  Clinical review 166: Growth hormone receptor antagonists.

Authors:  Alex F Muller; John J Kopchick; Allan Flyvbjerg; Aart Jan van der Lely
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

4.  Identification of a signal transduction pathway that regulates MMP-9 mRNA expression in glomerular injury.

Authors:  Irene von Lüttichau; Roghieh Djafarzadeh; Anna Henger; Clemens D Cohen; Anke Mojaat; Marianne Jochum; Christian Ries; Peter J Nelson; Matthias Kretzler
Journal:  Biol Chem       Date:  2002 Jul-Aug       Impact factor: 3.915

5.  Interaction between Smad-interacting protein-1 and the corepressor C-terminal binding protein is dispensable for transcriptional repression of E-cadherin.

Authors:  Leo A van Grunsven; Christine Michiels; Tom Van de Putte; Luc Nelles; Gunther Wuytens; Kristin Verschueren; Danny Huylebroeck
Journal:  J Biol Chem       Date:  2003-04-24       Impact factor: 5.157

6.  Abnormal serum growth hormone response to exercise in juvenile diabetics.

Authors:  A P Hansen
Journal:  J Clin Invest       Date:  1970-08       Impact factor: 14.808

7.  Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis.

Authors:  Yingjian Li; Junwei Yang; Chunsun Dai; Chuanyue Wu; Youhua Liu
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  Modulation of growth hormone signal transduction in kidneys of streptozotocin-induced diabetic animals: effect of a growth hormone receptor antagonist.

Authors:  Ana C P Thirone; John A Scarlett; Alessandra L Gasparetti; Eliana P Araujo; Maria H L Lima; Carla R O Carvalho; Lício A Velloso; Mario J A Saad
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

9.  Recruitment of a repressosome complex at the growth hormone receptor promoter and its potential role in diabetic nephropathy.

Authors:  P M Gowri; J H Yu; A Shaufl; M A Sperling; R K Menon
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

10.  Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue.

Authors:  Peter B Johansen; Yael Segev; Daniel Landau; Moshe Phillip; Allan Flyvbjerg
Journal:  Exp Diabesity Res       Date:  2003 Apr-Jun
View more
  18 in total

1.  Male bovine GH transgenic mice have decreased adiposity with an adipose depot-specific increase in immune cell populations.

Authors:  Fabian Benencia; Stephanie Harshman; Silvana Duran-Ortiz; Ellen R Lubbers; Edward O List; Lara Householder; Mawadda Al-Naeeli; Xiaoyu Liang; Lonnie Welch; John J Kopchick; Darlene E Berryman
Journal:  Endocrinology       Date:  2014-12-18       Impact factor: 4.736

2.  The novel role of TRPC6 in vitamin D ameliorating podocyte injury in STZ-induced diabetic rats.

Authors:  Xiaoliang Zhang; Zhixia Song; Yinfeng Guo; Min Zhou
Journal:  Mol Cell Biochem       Date:  2014-10-09       Impact factor: 3.396

3.  Abrogation of GH action in Kupffer cells results in increased hepatic CD36 expression and exaggerated nonalcoholic fatty liver disease.

Authors:  Sherry Zhang; Chunxia Lu; Arun K Das; Anil K Pasupulati; Ram K Menon
Journal:  Growth Horm IGF Res       Date:  2018-10-04       Impact factor: 2.372

4.  Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy.

Authors:  Rajkishor Nishad; Dhanunjay Mukhi; Syed V Tahaseen; Sathish Kumar Mungamuri; Anil K Pasupulati
Journal:  J Biol Chem       Date:  2019-09-11       Impact factor: 5.157

Review 5.  Glomerular endothelial cell injury and cross talk in diabetic kidney disease.

Authors:  Jia Fu; Kyung Lee; Peter Y Chuang; Zhihong Liu; John Cijiang He
Journal:  Am J Physiol Renal Physiol       Date:  2014-11-19

Review 6.  Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders.

Authors:  Rashita Makkar; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Aldulkarim M Meraya
Journal:  Neurotox Res       Date:  2022-04-27       Impact factor: 3.911

Review 7.  Metabolic syndrome and associated chronic kidney diseases: nutritional interventions.

Authors:  P Anil Kumar; P Swathi Chitra; G Bhanuprakash Reddy
Journal:  Rev Endocr Metab Disord       Date:  2013-09       Impact factor: 6.514

Review 8.  Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.

Authors:  John J Kopchick; Edward O List; Bruce Kelder; Elahu S Gosney; Darlene E Berryman
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

Review 9.  Human conditions of insulin-like growth factor-I (IGF-I) deficiency.

Authors:  Juan E Puche; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2012-11-14       Impact factor: 5.531

10.  Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis.

Authors:  Gal Finer; H William Schnaper; Yashpal S Kanwar; Xiaoyan Liang; Herbert Y Lin; Tomoko Hayashida
Journal:  Kidney Int       Date:  2012-04-25       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.